We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Carillion Plc | LSE:CLLN | London | Ordinary Share | GB0007365546 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLLN
RNS Number : 5437W
Carillion PLC
15 November 2017
15 November 2017
Carillion Joint Venture signs letter of award for contract in Oman
Carillion Alawi, a 50:50 Joint Venture with the Zawawi family, has signed a letter of award with the Oman Ministry of Health as the preferred bidder in respect of the design and build of the New Sultan Qaboos Hospital in Salalah. The contract has an estimated value of cGBP240 million to the Joint Venture.
The contract will consist of a two stage design and build process. The initial design and mobilisation phase, which will be directly funded by the customer, will commence immediately. The second phase would commence in 2018 once the design has been completed, the contract executed and funding finalised.
A further letter of award is due to be signed shortly by Carillion Alawi, also with the Oman Ministry of Health, in respect of a hospital in Khasab. The contract is on similar terms to those for the Salalah award and, if it were to go ahead, would have an estimated value of cGBP120m to the Joint Venture.
Both contracts are procured via lower risk procurement routes, for example through seeking support from UK Export Finance to secure project finance for customers. The Group continues to look at ways in which it can de-risk its operations in the Middle East, working with its partners in the region to secure the future of this business.
This and other Carillion news releases can be found at www.carillionplc.com.
For more information
Kellie McAvoy, Head of Investor Relations, or,
John Denning, Director Group Corporate Affairs, Carillion plc +44 (0) 1902 906333
Teneo Blue Rubicon
Charles Armitstead/Haya Herbert-Burns +44 (0) 207 420 3197
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTGGGMCGUPMUQA
(END) Dow Jones Newswires
November 15, 2017 02:01 ET (07:01 GMT)
1 Year Carillion Chart |
1 Month Carillion Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions